ＧＥＭ－９１获ＦＤＡ批准进行临床试验美国一个开发反义技术的公司一一海布里敦公司（Ｈｙｂｒｉｄｏｎ）已获ＦＤＡ批准，开始对反义寡聚核苷酸ＧＥＭ－９１进行Ｉａ期临床试验，用于治疗ＨＩＶ感染和艾滋病。试验将在伯明翰的亚拉巴马大学进行，有９１位志愿者参加。已... GEM-91 Approved by FDA for Clinical Trials Hybridon, an antisense technology company in the United States, has received FDA approval to begin Phase Ia clinical trials of the antisense oligonucleotide GEM-91, For the treatment of HIV infection and AIDS. The test will be conducted at the University of Alabama in Birmingham with 91 volunteers. Already ...